Respiratory syncytial virus (RSV) presents a significant disease burden in older adults, with no approved vaccines to protect against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the findings from an ongoing phase 3 study investigating vaccine efficacy of the AS01E-adjuvanted prefusion F protein candidate vaccine, RSVPreF3 OA, in adults ≥ 60 years of age (NCT04886596).
The abstract entitled: ‘Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age‘ (Abstract #LB745)’ was presented at IDWeek 2022, 19-23 October 2022.
Interviews available in this series:
Respiratory syncytial virus (RSV) – Health burden and current vaccine candidates
Questions: Michael Ison receives grant/research support from GSK.
- Could you tell us a little about the prefusion F protein candidate vaccine (RSVPreF3 OA)? (0:14)
- What were the methodology and eligibility criteria of your study evaluating RSVOreF3 OA? (0:56)
- What were the efficacy and safety findings of the study? (1:46)
- What will be the next steps in the clinical development of RSVOreF3 OA? (2:57)
Disclosures: Michael Ison receives grant/research support from GSK.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
